Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Trading on The Nasdaq Capital Market under the ticker symbol “PURR”
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 12/16/25 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] |
|
  |
157 |
| 08/26/25 | ARS | Annual Report to Security Holders |
|
134 | |
| 12/17/24 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
 |
96 |
| 08/19/24 | ARS | Annual report to security holders |
|
121 | |
| 12/14/23 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
|
82 |
| 08/07/23 | ARS | Annual report to security holders |
|
127 | |
| 12/15/22 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
|
79 |
| 12/17/21 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
|
82 |
| 12/17/20 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
|
139 |
| 04/22/20 | 10-K/A | Annual report pursuant to Section 13 and 15(d) |
|
16 |
